15.06.2025, 1063 Zeichen

Marinomed: Austrian science-based biotech company Marinomed Biotech AG has signed a binding term sheet with a Swiss pharmaceutical company for the development and marketing of Budesolv for the Swiss market. The new partner has been granted exclusive rights to sell and distribute Budesolv under its own brand. The deal includes the final development steps that are necessary for filing the marketing authorization in Switzerland. Marinomed is eligible to receive undisclosed upfront and milestone payments as well as royalties on sales. Marinomed retains all rights outside the territory and has the right to use the dossier compiled for Switzerland outside the territory. Andreas Grassauer, CEO of Marinomed comments: “We are confident that this deal is the first trigger for several other partnerships to come. We are convinced that a registration in Switzerland will enable opportunities in a series of other markets abroad.”
Marinomed Biotech: weekly performance: -2.63%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (09/06/2025)

Christian Drastil: Wiener Börse Plausch

Private Investor Relations Podcast #17: Mit Robert Gillinger und den Mitmachinfos zu unserem Finanzfilm-Award Golden Finance Cut

Bildnachweis

Aktien auf dem Radar:VIG, Kapsch TrafficCom, UBM, EuroTeleSites AG, Flughafen Wien, Palfinger, ATX, ATX Prime, ATX TR, ATX NTR, Bawag, Andritz, Mayr-Melnhof, Telekom Austria, RBI, voestalpine, SBO, Frequentis, Pierer Mobility, BKS Bank Stamm, Oberbank AG Stamm, Warimpex, Amag, EVN, CPI Europe AG, Lenzing, Österreichische Post, RHI Magnesita, Deutsche Telekom, Allianz, Fresenius.

---